Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Nixxy, Inc. reported a net loss of $3.88 million for the nine months ended September 30, 2026, an improvement from the $11.00 million loss in the prior year period. Revenue grew significantly to $74.51 million for the nine months, though the company continues to operate with a working capital deficit and an accumulated deficit of $117.68 million.
Invivyd, Inc. reported a significant increase in net loss to $119.3 million for the nine months ended September 30, 2026, compared to $41.4 million in the prior year, driven by a surge in R&D and SG&A expenses. Despite the higher loss, total revenue grew to $43.5 million from $36.2 million year-over-year, while cash and cash equivalents decreased to $126.4 million.
Prelude Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $142.7 million which is expected to fund operations into Q2 2028. The company advanced its clinical pipeline with the initiation of a Phase 1 study for PRT13722 in breast cancer and entered a clinical collaboration with Eli Lilly to evaluate combination therapies.
“The first three quarters of 2026 have been a period of strong execution for Prelude. We rapidly advanced two potential first-in-class programs into clinical development including PRT12396, a mutant-selective JAK2V617F inhibitor with disease-modifying potential in myeloproliferative neoplasms (MPNs) and PRT13722, a selective KAT6A degrader with the potential to improve the safety and efficacy of KAT6 inhibition, a clinically validated approach in HR+ breast cancer.”
Kris Vaddi, Ph.D., Chief Executive Officer of Prelude
Invivyd reported Q3 2026 financial results, highlighted by $15.4 million in PEMGARDA net product revenue, representing 18% year-over-year growth. The company also announced that Phase 3 clinical trial data for VYD2311 is expected imminently following regulatory dialogue with the FDA regarding accelerated approval pathways.
Term
Q3 2026
“We are excited about the progress made to advance VYD2311 to meet the urgent need for new options to prevent Americans from getting sick from COVID and suffering from the debilitating impact of Long COVID or COVID vaccine injury.”
Marc Elia, Chairman and Chief Executive Officer
“PEMGARDA’s continued growth, even in the face of declining COVID vaccine utilization and announcement of the termination of its Emergency Use Authorization in mid-2027, demonstrates clear demand for monoclonal antibodies.”
Lexeo Therapeutics reported total assets of $243.9 million as of September 30, 2026, a decrease from $268.7 million at year-end 2025. The company maintains a strong liquidity position with $90.2 million in cash and cash equivalents and $104.6 million in current U.S. Treasury securities to fund its ongoing clinical development of LX2006 and LX2020.
AirJoule Technologies reported Q3 2026 results, highlighting the completion of its BitSink acquisition and the delivery of its first AirJoule Prime system to a Data4 data center in France. The company also appointed Timothy N. White, an executive from Carrier Global Corporation, to its board of directors.
Term
Q3 2026
“This quarter marks an important step in AirJoule Technologies’ evolution. We expanded our commercial capabilities through the acquisition of BitSink, strengthened our market access through partnerships like Kubota, and sharpened our AirJoule product roadmap around our two highest-value platforms: Prime for water generation and Core DH for dehumidification.”
Matt Jore, Founder and Chief Executive Officer
“BitSink’s $15 million in signed purchase orders provides greater near-term revenue visibility, while our AirJoule products are moving through a more defined path to commercialization. We are deploying systems in customer environments, measuring real-world performance, and working to validate the economics that will support broader adoption.”
Xtant Medical reported Q3 2026 revenue of $24.3 million, a decrease from $33.3 million in the prior year primarily due to divested businesses and the absence of wound care licensing revenue. The company's Board of Directors also announced a formal strategic review process to evaluate operational improvements, capital structure alternatives, and potential business combinations or transactions.
Term
Q3 2026
“The Board is disappointed with Xtant’s financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable.”
Stavros Vizirgianakis, Chairman of the Board
“The Board’s priorities are clear: improve execution, improve financial performance, and maximize stockholder value through the strategic review process.”
Cypherpunk Technologies reported its Q3 2026 financial results, highlighted by the launch of its Zcash mining operations which generated $9.9 million in revenue from 8,967.29 ZEC mined. The company expanded its treasury to 341,858.75 ZEC, representing approximately 2.01% of the circulating supply, following its acquisition of a mining fleet from Moria Mining.
Term
Q3 2026
“The launch of Cypherpunk Mining in August was transformative, as it enabled the production of ZEC alongside our purchases and contributes to the security of the Zcash network. In the first six weeks of operation, our fleet earned 8,967.29 ZEC as a result of an exceptional 95% uptime, all of which was added to our treasury in a momentous third quarter for the company.”
Douglas E. Onsi, President and Chief Executive Officer
“The quarter marked a major milestone for Cypherpunk, and we are already planning for significant continued growth. We intend to increase our overall hashrate through additional equipment purchases with the goal of representing approximately 25% of the total Zcash network over time.”
Xtend AI Robotics, Inc. filed its 10-Q for the quarter ended September 30, 2026, following its recent merger with JFB Construction Holdings. The company reports a history of operating losses and limited revenue, focusing on the integration of its AI-driven robotics software across third-party unmanned platforms.
DUKE Robotics Corp. reported revenues of $448 thousand for the nine months ended September 30, 2026, with a net loss of $2.46 million. The company significantly strengthened its cash position to $6.4 million following a common stock offering that raised $7.26 million in net proceeds.
Elauwit Connection reported Q3 2026 financial results featuring a 104% sequential revenue increase to $5.6 million, driven by a ramp in construction activity. Key growth indicators showed strength as billed units rose 140% year-over-year and monthly recurring revenue (MRR) grew 66% to $539,000.
Instil Bio reported third quarter 2026 financial results, highlighting a cash position of $67.1 million which is expected to fund operations through 2027. The company is transitioning to an asset-focused development model through subsidiaries while reporting a significantly narrowed net loss compared to the prior year period.
Vycor Medical reported Q3 2026 revenue of $0.41M, a 19% decrease year-over-year, primarily due to higher-than-normal bulk orders in the prior year period. Despite the revenue decline, the company maintained a high gross margin of 85% and reported a nine-month operating profit of $80,083.
Cypherpunk Technologies reported a significant turnaround for the nine months ended September 30, 2026, with net income of $268.2 million compared to a net loss of $35.4 million in the prior year, primarily driven by a $299.3 million gain from the change in fair value of an embedded derivative. The company also launched mining operations, generating $9.9 million in revenue, and significantly strengthened its balance sheet through ATM stock sales and digital asset appreciation.
Blackstone Digital Infrastructure Trust Inc. completed its IPO in May 2026, raising approximately $1.9 billion in net proceeds to invest in data center properties. As of September 30, 2026, the company had not yet purchased any investments, reporting a net income of $22.7 million for the nine months ended primarily driven by interest income on cash holdings.
Blackstone Digital Infrastructure Trust Financial Results
Blackstone Digital Infrastructure Trust (BXDC) reported its third-quarter 2026 financial results, featuring net income of $15.6 million and FFO of $0.15 per share. The company also highlighted its inaugural investment in thirteen newly constructed data centers through a sale-leaseback transaction with Amazon.
Counterparty
Amazon
“Today marks an important milestone for BXDC with our inaugural investment in thirteen newly constructed data centers across two campuses through a sale-leaseback with Amazon. We believe this transaction delivers highly compelling risk-adjusted returns and establishes a strong foundation for long-term shareholder value creation. Importantly, it highlights our ability to source unique investment opportunities as well as the evolution of our investible universe, as the hyperscaler sale-leaseback channel doubles our total addressable market. We believe BXDC is exceptionally well-positioned to capitalize on this growing opportunity set.”
Rein Therapeutics reported a net loss of $17.8 million for the nine months ended September 30, 2026, compared to $17.9 million in the prior year. The company significantly strengthened its balance sheet through common stock issuances, ending the period with $35.5 million in cash and short-term investments compared to $3.2 million at the end of 2025.
Jaguar Health reported a significant increase in total revenue to $23.8 million for the nine months ended September 30, 2026, primarily driven by $20.9 million in license revenue. Despite this, the company recorded a net loss of $9.9 million for the period, though this was a substantial improvement from the $30.8 million net loss in the prior year period.
Aramark reported record fiscal 2026 results with revenue increasing 9% to exceed $1.9 billion in annualized gross new business and a record 97% client retention rate. The company's board authorized a new $1 billion share repurchase program and increased the quarterly dividend by 17%, reflecting strong cash flow generation and a reduced leverage ratio of 2.7x.
Readvantage Corp. reported a net loss of $10,883 for the quarter ended September 30, 2026, an improvement from a $37,931 loss in the prior year period. Revenue increased to $12,000, primarily driven by a one-time web development services engagement, while the company continues to maintain a stockholders' deficit of $143,465.
Unicycive Therapeutics reported a net loss of $7.0 million for the quarter ended September 30, 2026, compared to $6.0 million in the prior year period. The company's cash position strengthened to $42.0 million, supported by $39.0 million in net proceeds from financing activities during the first nine months of 2026.
22nd Century Group reported a net loss of $9.4 million for the nine months ended September 30, 2026, compared to a $2.2 million loss in the prior year period. The company experienced a significant decrease in total assets from $27.0 million to $23.4 million and recorded substantial deemed dividends related to the redemption of Series A and B convertible preferred stock.
Family Office of America, Inc. reported net revenues of $1,713,564 for the nine months ended September 30, 2026, compared to zero revenue in the prior year period. The company achieved a net profit of $97,281 for the nine-month period, a significant improvement from the $249,493 net loss reported in 2025.
JS Beauty Land Network Technology Inc. reported zero revenue for the nine months ended September 30, 2026, as it currently has no substantive business operations. The company incurred a net loss of $190,981 and faces a working capital deficit of $262,084, leading to substantial doubt about its ability to continue as a going concern.
Estrella Immunopharma reported a net loss of $11.98 million for the nine months ended September 30, 2026, compared to $12.45 million in the prior year period. The company's cash position decreased significantly to $92,458, while total stockholders' deficit widened to $13.97 million as research and development expenses remained the primary driver of operating costs.
Powerus Corp reported a net loss of $1.64 million for the nine months ended September 30, 2026, an improvement from the $2.55 million loss in the prior year period. Total revenue grew to $2.62 million, driven primarily by golf operations, while the company significantly increased its asset base through a $20 million investment in a convertible note.
Healthier Choices Management Corp. reported a significant decline in revenue to $76 for the quarter ended September 30, 2026, compared to $199 in the prior year, while narrowing its net loss to $315,418 from $2,076,113. The company's balance sheet shows a substantial decrease in total assets to $171,508 and a stockholders' deficit of $1,764,596 as it continues to focus on monetizing its intellectual property.
BioCorRx Inc. reported a net loss of $2,707,744 for the nine months ended September 30, 2026, compared to a loss of $2,921,916 in the prior year period. Total revenues decreased significantly to $126,690 from $527,047, while the company continues to rely heavily on grant income, which totaled $1,810,748 for the first nine months of 2026.
ClimateRock reported a net loss of $600,195 for the nine months ended September 30, 2026, compared to a loss of $844,755 in the prior year period. The company is a shell entity focused on a business combination, with total liabilities of $11,055,806 and a shareholders' deficit of $10,896,772 as of the reporting date.
Trutankless, Inc. reported a significant increase in net sales to $1.84 million for the nine months ended September 30, 2026, compared to $748,491 in the prior year. However, the company experienced a substantial net loss of $17.02 million, driven by high consulting fees and a $7.49 million non-cash charge related to the change in fair value of stock payables liabilities.